| P2093 | author name string | Michael B Atkins | |
| | Ryan J Sullivan | |
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| | CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations | Q24618486 |
| | Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 |
| | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 |
| | Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases | Q37480713 |
| | A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study | Q38517711 |
| | BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. | Q39920726 |
| | Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 |
| | The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways | Q39992436 |
| | Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice | Q40131849 |
| | CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. | Q40155722 |
| | Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells | Q40396792 |
| | Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 |
| | Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma | Q40534845 |
| | Chemosensitisation of malignant melanoma by BCL2 antisense therapy | Q40611574 |
| | Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma | Q40912648 |
| | A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors | Q40997984 |
| | Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas | Q42810281 |
| | Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines | Q42818580 |
| | Isolation of a tumor factor responsible for angiogenesis | Q42835506 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 |
| | The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 |
| | Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. | Q44071998 |
| | Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array | Q44594958 |
| | Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. | Q45197745 |
| | Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. | Q46106546 |
| | KIT gene mutations and copy number in melanoma subtypes | Q46267082 |
| | Effectively targeting BRAF in melanoma: a formidable challenge | Q46424236 |
| | A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel | Q46448115 |
| | Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis | Q46538518 |
| | Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 |
| | Phase II study of perifosine in previously untreated patients with metastatic melanoma | Q46611178 |
| | Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 |
| | The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 |
| | A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. | Q51751812 |
| | Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. | Q54795672 |
| | Phase I/II trial of tremelimumab in patients with metastatic melanoma | Q56900159 |
| | MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 |
| | EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 |
| | Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate | Q27824866 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 |
| | Major response to imatinib mesylate in KIT-mutated melanoma. | Q27851428 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | Vindesine as a single agent in the treatment of advanced malignant melanoma | Q28327120 |
| | Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma | Q28378420 |
| | BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 |
| | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 |
| | Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control | Q30485941 |
| | Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. | Q33337168 |
| | A phase II study of bortezomib in the treatment of metastatic malignant melanoma | Q33366244 |
| | CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium | Q33367168 |
| | Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer | Q33369361 |
| | Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group | Q33372613 |
| | Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma | Q33379895 |
| | Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. | Q33382481 |
| | Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma | Q33476213 |
| | Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine | Q33887196 |
| | Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop | Q34075619 |
| | High frequency of BRAF mutations in nevi | Q34160519 |
| | PDGFRA activating mutations in gastrointestinal stromal tumors. | Q34169772 |
| | Blocking oncogenic Ras signaling for cancer therapy | Q34311585 |
| | Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 |
| | Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c | Q34600089 |
| | Elesclomol induces cancer cell apoptosis through oxidative stress | Q34812609 |
| | Phosphoinositide 3-kinase in disease: timing, location, and scaffolding | Q36076050 |
| | Raf: a strategic target for therapeutic development against cancer | Q36260492 |
| | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 |
| | Lack of clinical efficacy of imatinib in metastatic melanoma | Q36616712 |
| | A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma | Q36621278 |
| | A novel AKT3 mutation in melanoma tumours and cell lines | Q36944047 |
| | Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic | Q36945203 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1205-1216 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond | |
| P478 | volume | 19 | |